Squarepoint
SLS icon

Squarepoint’s SELLAS Life Sciences SLS Stock Holding History

Squarepoint’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-130,100
Closed -$141K – 5006
2025
Q1 		$141K Buy
+130,100
New +$154K ﹤0.01% 4129
2024
Q4 		– Sell
-16,900
Closed -$21.1K – 5463
2024
Q3 		$21.1K Buy
+16,900
New +$20.7K ﹤0.01% 4021

Other funds holding SLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Squarepoint's SLS Position: Q2 2026 in Review

Squarepoint reduced its SELLAS Life Sciences (SLS) stake by 86% in Q2 2026, selling an estimated $443K and leaving 10,512 shares worth $155K. The position accounts for ﹤0.01% of the portfolio, ranked #4124.

Squarepoint first reported a position in SLS in Q2 2017 and has held it in 9 quarters since. The position peaked at $316K in Q1 2026. 193 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

  • Squarepoint held 10,512 shares of SELLAS Life Sciences worth $155K as of Q2 2026.
  • Squarepoint sold 64,239 SELLAS Life Sciences shares in Q2 2026, an estimated $443K.
  • SELLAS Life Sciences made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #4124 holding.
  • Squarepoint first reported a position in SELLAS Life Sciences in Q2 2017 and has held it in 9 quarters since.
  • Squarepoint's SELLAS Life Sciences position peaked at $316K in Q1 2026.
  • 193 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.